Skip to main content

Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

The Original Article was published on 25 March 2021

Correction to: Pediatr Rheumatol 19, 46 (2021)

https://doi.org/10.1186/s12969-021-00514-4

Following publication of the original article [1], the authors identified some errors in the text of the article. Correct text parts should be as follows:

  1. 1.

    Results section in Abstract should read as follows: All 35 RCTs reported efficacy while 34/35 provided safety outcomes and 16/35 provided pharmacokinetic data.

  2. 2.

    Table 4 should have IL-1 inhibitor canakinumab 4mg/kg single dose

  3. 3.

    Results section text should be as follows: In march 2020, the FDA has approved all 23 reviewed drugs, including bDMARDs and JAK inhibitors for adult rheumatology, whereas the EMA has approved 22 (Table 6).

Reference

  1. 1.

    Welzel, et al. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol. 2021;19:46. https://doi.org/10.1186/s12969-021-00514-4.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tatjana Welzel.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Welzel, T., Winskill, C., Zhang, N. et al. Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials. Pediatr Rheumatol 19, 124 (2021). https://doi.org/10.1186/s12969-021-00593-3

Download citation